The DOI matches its Crossref record.
Binding of IL-1 alpha , IL-1 beta , and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids.
Abstract
These studies have examined the binding of the three IL-1 ligands, IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist (IL-1 ra), to soluble forms of types I and II IL-1Rs (sIL-1RI and sIL-1RII). This interaction was measured in direct binding experiments, in which the ligands bound to immobilized sIL-1R, and in inhibition experiments, in which sIL-1R in solution inhibited the binding of IL-1 ligands to immobilized sIL-1R. In addition, the effects of sIL-1R on the detection of IL-1 ligands by ELISA were examined. Finally, levels of sIL-1R in synovial fluid samples were determined, and their effects on measurement of IL-1 in these samples were estimated. IL-1 beta bound more avidly to sIL-1RII than IL-1 alpha or IL-1ra, primarily because of a slow dissociation rate. In contrast, IL-1 ra bound more avidly than IL-1 alpha or IL-1 beta to sIL-1RI, again because of a slow dissociation rate. sIL-1RII and sIL-1RI inhibited the detection of IL-1 beta and IL-1ra, respectively, by ELISA. Low levels of sIL-1RI (approximately 1.0-2.5 ng/ml) were present in all synovial fluids, irrespective of the degree of inflammation, and were correlated inversely with the levels of measured IL-1ra. In contrast, higher levels of sIL-1RII (approximately 10-20 ng/ml) were found in inflammatory synovial fluids and were not correlated with IL-1ra levels. IL-1 beta could not be detected in any synovial fluid. These results suggest that some IL-1 beta and IL-1ra may be bound in vivo to sIL-1RII and sIL-1RI, respectively, leading to underestimations of cytokine concentrations in body fluids when measured by ELISA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734
Lee, D. M., & Weinblatt, M. E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06075-5 · Cited by 1,247
INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology
Arend, W. P., Malyak, M., Guthridge, C. J., & Gabay, C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.27 · Cited by 1,071
Self-citationLeptin in the regulation of immunity, inflammation, and hematopoiesis
Fantuzzi, G., & Faggioni, R. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.68.4.437 · Cited by 980
“Alternatively, similar to the soluble receptors for IL-1 or tumor necrosis factor, it may function as an inhibitor of leptin activity [53, 54].”
BackgroundInterleukin-1, Interleukin-1 Receptors and Interleukin-1 Receptor Antagonist
Dinarello, C. A. (1998) · International Reviews of Immunology · doi:10.3109/08830189809043005 · Cited by 761
Dinarello, C. A. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(97)00023-3 · Cited by 582
Palomo, J., Dietrich, D., Martin, P., Palmer, G., & Gabay, C. (2015) · Cytokine · doi:10.1016/j.cyto.2015.06.017 · Cited by 447
Regulation of serum amyloid A protein expression during the acute-phase response
JENSEN, L. E., & WHITEHEAD, A. S. (1998) · Biochemical Journal · doi:10.1042/bj3340489 · Cited by 411
Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines
Mantovani, A., Locati, M., Vecchi, A., Sozzani, S., & Allavena, P. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01941-x · Cited by 383
Anti-Cytokine Therapy for Rheumatoid Arthritis
Maini, R. N., & Taylor, P. C. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.207 · Cited by 376
Kim, S.-H., Eisenstein, M., Reznikov, L., Fantuzzi, G., Novick, D., Rubinstein, M., & Dinarello, C. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.3.1190 · Cited by 341
Böni-Schnetzler, M., Thorne, J., Parnaud, G., Marselli, L., Ehses, J. A., Kerr-Conte, J., Pattou, F., Halban, P. A., Weir, G. C., & Donath, M. Y. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0396 · Cited by 320
Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein.
Gabay, C., Smith, M. F., Eidlen, D., & Arend, W. P. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119488 · Cited by 319
Self-citationArterial Inflammation in Mice Lacking the Interleukin 1 Receptor Antagonist Gene
Nicklin, M. J. H., Hughes, D. E., Barton, J. L., Ure, J. M., & Duff, G. W. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.303 · Cited by 317
Vincent, J. A., & Mohr, S. (2007) · Diabetes · doi:10.2337/db06-0427 · Cited by 298
Ghivizzani, S. C., Lechman, E. R., Kang, R., Tio, C., Kolls, J., Evans, C. H., & Robbins, P. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4613 · Cited by 287
Etiology and Pathogenesis of Rheumatoid Arthritis
Firestein, G. S. (2017) · Kelley and Firestein's Textbook of Rheumatology · doi:10.1016/b978-0-323-31696-5.00069-3 · Cited by 278
Heaney, M., & Golde, D. (1996) · Blood · doi:10.1182/blood.v87.3.847.bloodjournal873847 · Cited by 272
IL-1 receptor 2 (IL-1R2) and its role in immune regulation
Peters, V. A., Joesting, J. J., & Freund, G. G. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.11.006 · Cited by 264
Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation
DINARELLO, C. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.03.010 · Cited by 195
Identification of functional endothelial protein C receptor in human plasma.
Kurosawa, S., Stearns-Kurosawa, D. J., Hidari, N., & Esmon, C. T. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119548 · Cited by 154
“The latter mechanism is used by the IL-1 receptor system in which the soluble isoforms of both IL-1 receptors are generated by proteolytic cleavage, and tightly regulate the responsiveness to IL-1a and IL-1b (45).”
BackgroundThe generation and function of soluble apoE receptors in the CNS
Rebeck, G. W., LaDu, M. J., Estus, S., Bu, G., & Weeber, E. J. (2006) · Molecular Neurodegeneration · doi:10.1186/1750-1326-1-15 · Cited by 66
Metadata
- Authors
- Arend, W. P., Malyak, M., Smith, M. F., Whisenand, T. D., Slack, J. L., Sims, J. E., Giri, J. G., & Dower, S. K.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1994-11
- Volume
- 153
- Issue
- 10
- Pages
- 4766-4774
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1910189841
- Cited by
- 241
- References
- 0
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.